Home / Business News

Business News

Bayer Collaborates with Children’s Hospital of Philadelphia to Research Novel Small Molecule Therapies for Oral Treatment of Hemophilia

WHIPPANY, N.J., Dec. 5, 2019 /PRNewswire/ — Bayer announced today that it has entered into a three-year collaboration agreement with Children’s Hospital of Philadelphia (CHOP) for the discovery and development of small molecules (SMOLs) to develop a first-in-class oral non-replacement therapy (NRT) for the treatment of hemophilia A and B. …

Read More »

Takeda and Enzyre to Develop Diagnostic Device Allowing Hemophilia Patients to Determine their Coagulation Status at Home

NIJMEGEN, Netherlands, Dec. 5, 2019 /PRNewswire/ — Enzyre, which is developing breakthrough ambulant diagnostic technology for coagulation testing, today announced that it has entered into a research collaboration agreement with Takeda Pharmaceutical Company Limited (Takeda) to develop a diagnostic device that will enable hemophilia patients to determine their coagulation status …

Read More »

AstraZeneca Collaborates with Gatehouse Bio to Use its AI-Powered Analytics Platform to Identify Drug Targets in Respiratory and Cardiovascular Diseases

BOSTON–(BUSINESS WIRE)–Gatehouse Bio, a pioneer in next-generation therapeutics, is collaborating with AstraZeneca, a global science-led biopharmaceutical company, to explore the identification of new targets for respiratory and cardiovascular diseases using Gatehouse Bio’s Artificial Intelligence (AI)-powered platform. Gatehouse Bio’s ‘sRNAlytics platform’ identifies novel small RNA (sRNA) signatures and illuminates molecular pathways …

Read More »

Foundation Medicine Expands Indication for FoundationOne CDx as a Companion Diagnostic for Piqray

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Foundation Medicine, Inc. today announced it has received approval from the U.S. Food and Drug Administration (FDA) for FoundationOne®CDx to be used as a companion diagnostic for Piqray® (alpelisib) in combination with fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor (HR)-positive, human epidermal growth factor receptor …

Read More »

LEO Pharma and Portal Instruments Announce Collaboration to Develop Needle-Free Drug Delivery Device

BALLERUP, Denmark & CAMBRIDGE, Mass.–(BUSINESS WIRE)–LEO Pharma A/S and Portal Instruments today announced a global collaboration and license agreement to develop Portal’s innovative needle-free drug delivery system for use in combination with LEO Pharma’s portfolio of investigational and approved medicines. Portal Instruments has developed a needle-free jet injector platform to …

Read More »

Veracyte Acquires Exclusive License to NanoString Diagnostics Platform, Positioning Veracyte To Expand Its Genomic Testing Business Globally

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Veracyte (Nasdaq: VCYT) today announced that it has executed a definitive agreement with NanoString for the exclusive global license to the nCounter® platform for diagnostic use. The strategic transaction positions Veracyte to expand its genomic diagnostics business globally, with the ability to deliver its advanced genomic tests to …

Read More »

ArcherDX Announces Partnership with Illumina to Develop In-Vitro Diagnostic Tests

BOULDER, Colo., Dec. 3, 2019 /PRNewswire/ — ArcherDX, Inc., a growth-stage molecular diagnostics company dedicated to developing breakthrough solutions that advance personalized genomic medicine, today announced a non-exclusive partnership with Illumina, Inc. (NASDAQ: ILMN) to develop in-vitro diagnostic (IVD) tests for Archer’s planned portfolio of next-generation sequencing (NGS)-based companion diagnostics. …

Read More »

Astellas Enters into Definitive Agreement to Acquire Audentes Therapeutics for $3 Billion

TOKYO & SAN FRANCISCO–(BUSINESS WIRE)–Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and Audentes Therapeutics, Inc. (NASDAQ: BOLD, Chairman and CEO: Matthew R. Patterson, “Audentes”), today announced that they have entered into a definitive agreement for Astellas to acquire Audentes at a price of US$60.00 per …

Read More »

Seattle Genetics and Astellas Collaborate with Merck to Evaluate Enfortumab Vedotin with Keytruda in Patients with Metastatic Urothelial Cancer

BOTHELL, Wash. & TOKYO–(BUSINESS WIRE)–Seattle Genetics, Inc. (Nasdaq:SGEN) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”), today announced a clinical collaboration agreement with Merck, known as MSD outside the United States and Canada through a subsidiary, to evaluate the combination of Seattle Genetics’ and Astellas’ antibody-drug conjugate (ADC) …

Read More »

Baxter Buys Sanofi’s Seprafilm Unit for $350 Million in Cash

DEERFIELD, Ill.–(BUSINESS WIRE)–Baxter International Inc. (NYSE:BAX), a leading global medical products company, today entered into a definitive agreement to acquire Seprafilm Adhesion Barrier and related assets from Sanofi. The agreement is the latest example of Baxter’s continued focus on acquiring products and technologies that have a strong strategic fit with the company’s …

Read More »